The 2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit is the only event uniting key B&T cell decision-makers to advance the therapeutic future of autoimmune diseases.
This cross-disciplinary program featuring keynote talks from 32+ clinical KOLs from large pharma, biotech and academia, will give you insight into the full therapeutic opportunity of drug candidates against various plasma, B and T cell targets.
Unite with other B & T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells, B cell functions (autoantibody production, antigen presentation, T cell help & cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression.
View our full event guide to see our complete speaker line-up, latest agenda, and workshop details. https://ter.li/0zk3pp
Key Discussions you Can’t Afford to Miss:
- Delve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro, Polyneuron, Apitope, NYSCF, UTHSC & Cabaletta Bio
- Discover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co, UCL, Kyverna, Immunic AG, Nurix & GSK
- Uncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio, Cytocom, Horizon, AltruBio & Novartis
- Explore targets, considerations and strategy for targeting autoantibody producing plasma cells, organ specific and systemic diseases with UCB, Provention Bio, IM Therapeutics & Biogen
- Optimize application and patient outlook through combination strategies, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation, Bristol-Myers Squibb & Eli Lilly & Co
Find out more https://ter.li/0zk3pp